§: three-arm trial. Diagnostic criteria: symptoms: ①prostate or pelvic region pain history: persistent or recurrent discomfort or pain in the prostate or pelvic area more than 3 months; ②lower urinary tract pathologies or genitourinary pain in the prostate or pelvic area more than 3 months; ③sexual dysfunction: impotence, premature ejaculation, spermatorrhea, sexual desire decreases; physical examination; ④prostate palpitation: abnormal size, uneven surface, local tenderness, or a lot of prostate fluid flow; auxiliary examination; ⑤ultrasonic examination: a slightly deformed section but with no expansion, uneven and inconsistent capsule often accompanied with prostatolith, less or not a smooth echo of a prostatic capsule and less even or uneven internal echo; ⑥laboratory test: EPS (white blood cell >10/HP objective and reduced of lecithin capsule); NIH-CPSI: ⑦NIH-CPSI total score ≥15 scores; age: ⑧age ≥18; ⑨age ≤50. Outcomes: a. treatment efficacy; b. NIH-CPSI score; b1. pain score; b2. urinary symptom score; b3. quality of life score; c. IPSS score; d. recurrence rate; e. side-effect.
